Company Encyclopedia
View More
name
Xenetic Biosciences
XBIO.US
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery.
1.946 T
XBIO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking172/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-57.44%E
    • Profit Margin-110.40%E
    • Gross Margin100.00%A
  • Growth ScoreC
    • Revenue YoY13.30%B
    • Net Profit YoY22.59%B
    • Total Assets YoY-37.01%E
    • Net Assets YoY-43.78%E
  • Cash ScoreC
    • Cash Flow Margin-90.58%D
    • OCF YoY13.30%B
  • Operating ScoreC
    • Turnover0.44C
  • Debt ScoreA
    • Gearing Ratio21.94%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Xenetic Biosciences Extends Research Collaboration with Scripps Research to Advance DNase Platform

    Xenetic Biosciences Inc. has extended its research collaboration with The Scripps Research Institute and Dr. Alexey Stepanov’s laboratory for an additional four months starting November 1, 2025. The focus is on advancing Xenetic’s DNase I platform in combination with CAR T-cell therapies, aiming to improve responses to CAR-T cell therapy for hematologic and solid tumors. Preclinical studies have shown promising results, and the program is moving toward Phase 1 clinical development.

    Reuters·
    US
    XBIO
    +4.96%
    Reuters·
    US
    XBIO
    +4.96%

    Xenetic Biosciences Reports Q3 2025 Financial Results

    Xenetic Biosciences reported Q3 2025 financial results, showing a rise in royalty revenue to $1.03 million but a net loss of $509,940. Cash reserves decreased to $4.12 million, and liabilities increased to $1.11 million. R&D expenses rose to $756,482. The company is exploring strategic alternatives, including mergers or asset sales, and aims to advance its DNase technology into clinical trials while seeking additional funding.

    Tip Ranks·
    US
    XBIO
    +4.96%
    Tip Ranks·
    US
    XBIO
    +4.96%

    Xenetic Biosciences | 8-K: FY2025 Q3 Revenue: USD 1 M

    LB filings·
    US
    XBIO
    +4.96%
    LB filings·
    US
    XBIO
    +4.96%

    Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering

    Xenetic Biosciences reported a 67.2% increase in Q3 2025 revenue to $1.0 million, driven by increased royalty revenue from a sublicense agreement with Takeda Pharmaceuticals. The company ended the quarter with $4.1 million in cash and completed a $3.9 million public offering. Xenetic continues to advance its DNase I program and collaborate with institutional partners. This summary is based on AI-generated content by Public Technologies.

    Reuters·
    US
    XBIO
    +4.96%
    Reuters·
    US
    XBIO
    +4.96%

    Xenetic Biosciences | 10-Q: FY2025 Q3 Revenue: USD 1.027 M

    LB filings·
    US
    XBIO
    +4.96%
    LB filings·
    US
    XBIO
    +4.96%
    © 2025 Longbridge｜Disclaimer